---
layout: post
title: 2010 New Drug Approval - Pt. XI - Alcaftadine (Lastacaft)
date: '2010-09-03T11:49:00.036+01:00'
author: felix
tags:
- Small Molecule Drugs
- 2010 New Drugs
modified_time: '2010-12-24T09:20:38.905Z'
thumbnail: http://2.bp.blogspot.com/_SlPG9DIz_AA/TIHyRIdiyFI/AAAAAAAAA2Y/kmupTf93LdI/s72-c/images.jpeg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-2547645736041037679
blogger_orig_url: http://chembl.blogspot.com/2010/09/2010-new-drug-approval-pt-xi.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://2.bp.blogspot.com/_SlPG9DIz_AA/TIHyRIdiyFI/AAAAAAAAA2Y/kmupTf93LdI/s1600/images.jpeg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/_SlPG9DIz_AA/TIHyRIdiyFI/AAAAAAAAA2Y/kmupTf93LdI/s320/images.jpeg" /></a></div><center style="text-align: auto;"><br />
</center><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://www.sarfari.org/chembltools/autoicon/1,1,0,0,0,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="36" src="http://www.sarfari.org/chembltools/autoicon/1,1,0,0,0,1" width="320" /></a></div><div class="separator" style="clear: both; text-align: center;"><br />
</div><div class="separator" style="clear: both; text-align: center;">ATC code:&nbsp;</div><div class="separator" style="clear: both; text-align: center;"><br />
</div>The summer got in the way of a timely post on this new drug. On 28 July 2010, Alcaftadine was approved for the treatment of patients with allergic conjunctivitis as a 0.25% opthalmic solution.<br />
This allergic reaction is most familiar in patients with hay fever but can also be caused by other allergens such as dust mites, moulds, perfumes <i>etc</i>. It causes red, itchy and watery eyes.<br />
Allergic conjunctivitis is caused by a type I <a href="http://en.wikipedia.org/wiki/Hypersensitivity">hypersensitivity</a> reaction of the immune system. Antigenic epitopes of the allergen are detected by <a href="http://en.wikipedia.org/wiki/Immunoglobulin_E">IgE</a> antibodies which mediate the excessive activation of <a href="http://en.wikipedia.org/wiki/Mast_cell">mast cells</a> and <a href="http://en.wikipedia.org/wiki/Basophil_granulocyte">basophils</a>.&nbsp; The symptoms of allergic conjunctivitis are mainly caused by the release of <a href="http://en.wikipedia.org/wiki/Histamine">histamine</a> from these activated immune cells. Histamine increases the permeability of blood vessels and stimulates the activity of immune cells, through a number of differing histamine receptors.<br />
<br />
Alcaftadine and it's carboxylic acid metabolite (produced <i>via</i> a non P450 route) are antagonists of the H<sub>1</sub> histamine receptor (Uniprot: <b style="font-weight: normal;"><a href="http://www.uniprot.org/uniprot/P35367">P35367</a>)</b> and also inhibit histamine release.<br />
<br />
Alcaftadine is administered topically as a 0.25% solution. In a pharmakokinetics study, the plasma C<sub>MAX</sub> of Alcaftadine is 60pg/mL and occurs after 15 minutes, the plasma C<sub>MAX</sub> of the active metabolite is 10pg/mL and occurs after one hour. Plasma protein binding (ppb) for Alcaftadine is 39.2%, and for the carboxylic acid metabolite is 62.7%. The elimination half-life of the metabolite is appoximately 2 hours. The presence of the aldehyde is an unusual chemical feature in Alcaftadine, since aldehydes are usually quite reactive, as would be expected this group is readily metabolized to a carboxylic acid.<br />
<br />
The full prescribing information is <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022134s000lbl.pdf">here</a>.<br />
<br />
Adverse reactions may include eye irritation, eye redness, nasopharyngitis, headache and influenza.<br />
<br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://1.bp.blogspot.com/_HOcqqDQLBT8/TNA1qcpPYYI/AAAAAAAAAOY/eXMJjeEVLDw/s1600/alcaftadine.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="http://1.bp.blogspot.com/_HOcqqDQLBT8/TNA1qcpPYYI/AAAAAAAAAOY/eXMJjeEVLDw/s320/alcaftadine.png" width="234" /></a></div><div class="separator" style="clear: both; text-align: center;"></div><br />
<span class="Apple-style-span" style="font-family: Times, 'Times New Roman', serif;"><br />
</span><br />
<pre style="font-family: &quot;Courier New&quot;,Courier,monospace;"><span class="Apple-style-span">IUPAC: 11-(1-methylpiperidin-4-ylidene)-5,6-dihydro</span></pre><pre style="font-family: &quot;Courier New&quot;,Courier,monospace;"><span class="Apple-style-span">imidazo[2,3-b][3]</span><span class="Apple-style-span">benzazepine-3-carbaldehyde</span></pre><pre style="font-family: &quot;Courier New&quot;,Courier,monospace;"><span class="Apple-style-span">&nbsp;</span></pre><pre style="font-family: &quot;Courier New&quot;,Courier,monospace;"></pre><div style="font-family: &quot;Courier New&quot;,Courier,monospace;"></div><div style="font-family: &quot;Courier New&quot;,Courier,monospace;"><span style="font-size: small;"><span class="Apple-style-span">SMILES:</span></span><span class="Apple-style-span"> CN1CCC(CC1)=C2c3ccccc3CCn4c(C=O)cnc24</span></div><div style="font-family: &quot;Courier New&quot;,Courier,monospace;"><span class="Apple-style-span" style="font-size: small; white-space: pre;"><span class="Apple-style-span">InChI: 1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-</span></span><br />
<span class="Apple-style-span" style="font-size: small; white-space: pre;"><span class="Apple-style-span">5-3-2-4-14(17)8-11-22-</span></span><span style="font-size: small;"><span class="Apple-style-span">16(13-23)12-20-19(18)22/</span></span><br />
<span style="font-size: small;"><span class="Apple-style-span">h2-5,12-13H,6-11H2,1H3</span></span></div><pre style="font-family: Times,&quot;Times New Roman&quot;,serif;"><span style="font-size: small;">&nbsp;</span></pre>Alcaftadine was developed by the <a href="http://www.janssenpharmaceutica.be/index_E.asp">Janssen Research Foundation</a> and will be marketed in the US under the name Lastacaft by <a href="http://www.jnjvisioncare.com/index.jsp">Vistakon Pharmaceuticals</a>.